BC Innovations | Jan 30, 2014
Cover Story

BBB-conquering antibodies

Roche has developed a new transferrin receptor -targeting strategy that dramatically increased delivery of an antibody to the brain. 1 The key advance was slimming the technology, dubbed Brain Shuttle, down to a single transferrin...
BC Week In Review | Sep 2, 2013
Company News

Ambrx management update

Ambrx Inc. , La Jolla, Calif.   Business: Chemistry   Hired: Peter Kiener as CSO, formerly president and CEO of Zyngenia Inc.  ...
BC Week In Review | Mar 18, 2013
Clinical News

Zyngenia preclinical data

In a mouse xenograft model of pancreatic cancer, Zyngenia's cetuximab-based bispecific zybody targeting EGFR and epidermal growth factor receptor 3 ( EGFR3 ; HER3 ; ErbB3 ) significantly inhibited tumor growth vs. cetuximab (p=0.045). A zybody is...
BC Week In Review | Mar 18, 2013
Clinical News

Zyngenia preclinical data

In a mouse xenograft model of ovarian cancer, Zyngenia's trastuzumab-based bispecific zybody targeting angiopoietin 2 ( ANG2 ; ANGPT2 ) and epidermal growth factor receptor 2 ( EGFR2 ; HER2 ; ErbB2 ; neu) significantly inhibited tumor growth...
BC Week In Review | Jun 11, 2012
Company News

Zyngenia management update

Interim CMO David Parkinson, who remains chairman of the clinical advisory board Zyngenia Inc. , Gaithersburg, Md.   Business: Cancer, Autoimmune, Inflammation   Hired: Frank Hsu as CMO, formerly senior medical director in the transplant and...
BC Week In Review | Apr 30, 2012
Company News

Zyngenia management update

Zyngenia Inc. , Gaithersburg, Md.   Business: Cancer, Autoimmune, Inflammation   Hired: David Parkinson as a director and interim CMO, a newly created position, formerly president and CEO of Nodality Inc.  ...
BC Week In Review | Dec 19, 2011
Company News

Zyngenia management update

Zyngenia Inc. , Gaithersburg, Md.   Business: Cancer, Autoimmune, Inflammation   Hired: Daniel Menichella as CBO, formerly SVP of corporate development and strategy at Talecris Biotherapeutics Inc.   Promoted: David Hilbert to chief scientific officer and...
BC Week In Review | May 23, 2011
Company News

Resolve Therapeutics board of directors update

Resolve Therapeutics LLC , Kirkland, Wash.   Business: Autoimmune   Appointed: Peter Kiener, CEO of Zyngenia Inc. , as chairman; and Somu Subramaniam, founder and managing partner of New Science Ventures  ...
BC Week In Review | Sep 13, 2010
Financial News

Zyngenia financial update

Zyngenia raised $15 million in an extension of a series A round, bringing the total raised to $25 million. Existing investor New Enterprise Associates participated in the extension. Zyngenia raised $10 million in the round...
BC Extra | Sep 9, 2010
Financial News

Zyngenia raises $15 million

Zyngenia Inc. (Gaithersburg, Md.) raised $15 million in an extension of a series A round, bringing the total raised to $25 million. Existing investor New Enterprise Associates participated in the extension. Zyngenia is developing Zybodies...
Items per page:
1 - 10 of 15
BC Innovations | Jan 30, 2014
Cover Story

BBB-conquering antibodies

Roche has developed a new transferrin receptor -targeting strategy that dramatically increased delivery of an antibody to the brain. 1 The key advance was slimming the technology, dubbed Brain Shuttle, down to a single transferrin...
BC Week In Review | Sep 2, 2013
Company News

Ambrx management update

Ambrx Inc. , La Jolla, Calif.   Business: Chemistry   Hired: Peter Kiener as CSO, formerly president and CEO of Zyngenia Inc.  ...
BC Week In Review | Mar 18, 2013
Clinical News

Zyngenia preclinical data

In a mouse xenograft model of pancreatic cancer, Zyngenia's cetuximab-based bispecific zybody targeting EGFR and epidermal growth factor receptor 3 ( EGFR3 ; HER3 ; ErbB3 ) significantly inhibited tumor growth vs. cetuximab (p=0.045). A zybody is...
BC Week In Review | Mar 18, 2013
Clinical News

Zyngenia preclinical data

In a mouse xenograft model of ovarian cancer, Zyngenia's trastuzumab-based bispecific zybody targeting angiopoietin 2 ( ANG2 ; ANGPT2 ) and epidermal growth factor receptor 2 ( EGFR2 ; HER2 ; ErbB2 ; neu) significantly inhibited tumor growth...
BC Week In Review | Jun 11, 2012
Company News

Zyngenia management update

Interim CMO David Parkinson, who remains chairman of the clinical advisory board Zyngenia Inc. , Gaithersburg, Md.   Business: Cancer, Autoimmune, Inflammation   Hired: Frank Hsu as CMO, formerly senior medical director in the transplant and...
BC Week In Review | Apr 30, 2012
Company News

Zyngenia management update

Zyngenia Inc. , Gaithersburg, Md.   Business: Cancer, Autoimmune, Inflammation   Hired: David Parkinson as a director and interim CMO, a newly created position, formerly president and CEO of Nodality Inc.  ...
BC Week In Review | Dec 19, 2011
Company News

Zyngenia management update

Zyngenia Inc. , Gaithersburg, Md.   Business: Cancer, Autoimmune, Inflammation   Hired: Daniel Menichella as CBO, formerly SVP of corporate development and strategy at Talecris Biotherapeutics Inc.   Promoted: David Hilbert to chief scientific officer and...
BC Week In Review | May 23, 2011
Company News

Resolve Therapeutics board of directors update

Resolve Therapeutics LLC , Kirkland, Wash.   Business: Autoimmune   Appointed: Peter Kiener, CEO of Zyngenia Inc. , as chairman; and Somu Subramaniam, founder and managing partner of New Science Ventures  ...
BC Week In Review | Sep 13, 2010
Financial News

Zyngenia financial update

Zyngenia raised $15 million in an extension of a series A round, bringing the total raised to $25 million. Existing investor New Enterprise Associates participated in the extension. Zyngenia raised $10 million in the round...
BC Extra | Sep 9, 2010
Financial News

Zyngenia raises $15 million

Zyngenia Inc. (Gaithersburg, Md.) raised $15 million in an extension of a series A round, bringing the total raised to $25 million. Existing investor New Enterprise Associates participated in the extension. Zyngenia is developing Zybodies...
Items per page:
1 - 10 of 15